TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01217138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine autoinjector
Description: We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.

Intervention type: DEVICE
Group type: OTHER
Intervention: Epinephrine autoinjector
Description: We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
Study: NCT04250389

Intervention type: OTHER
Intervention: Hemodynamic assessment (micro and macrocirculatory)
Description: Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases.
Study: NCT00374985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin
Description: weekly doses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: regular fractions
Study: NCT02131493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1, Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Gemcitabine
Study: NCT00710788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer phosphate-binders
Description: 1600 mg/day for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate 1 g/day for 2 years
Study: NCT01407133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)
Description: The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)
Description: Same sound level as active rTMS, but magnetic field strongly attenuated
Study: NCT01498666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri protectis
Description: 1 tablet once daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 tablet once daily for 4 weeks
Study: NCT04802915

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative ERM and ILM staining with their assessment and removal
Description: ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
Study: NCT00170755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
Study: NCT02269943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Study: NCT02136485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: 8 sessions of MBSR

Intervention type: OTHER
Group type: OTHER
Intervention: waiting list control
Study: NCT00598481

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Therapy
Description: Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
Study: NCT03798457

Intervention type: OTHER
Intervention: No intervention
Description: In this study there is no intervention
Study: NCT02435264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthier Dining Program Intervention
Description: The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
Study: NCT00425308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus + Cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study: NCT02918981

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.6 g Whey protein + 1.25 g leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water control
Study: NCT01050478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: paliperidone ER at 2 dosage levels (6 and 9 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Description: Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
Study: NCT05629000

Intervention type: PROCEDURE
Intervention: Carotid revascularization
Description: All patients received carotid revascularization surgery at Peking Union Medical College Hospital.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-PWI
Description: Multi-modal MRI before and after surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: CTA
Description: CTA before and after surgery.
Study: NCT00425308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study: NCT01852721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Men and Mediterranean diet
Description: The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Women and Mediterranean diet
Description: Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
Study: NCT01111448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
Study: NCT04188392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: pimavanserin tablet
Study: NCT01440179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR3419
Description: Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
Study: NCT02588144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: [standard STN]
Description: High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: [STN+SNr]
Description: high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
Study: NCT01727427

Intervention type: DRUG
Intervention: Heparin, fondaparinux, vitamin-K antagonists, aspirin
Description: Parenteral or oral anticoagulant Antiplatelet agent
Study: NCT04076579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib taken by mouth twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin administered intravenously (IV) every 21 days
Study: NCT01161121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine
Description: Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
Study: NCT05629000

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: PET/MRI before surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound before and after surgery.
Study: NCT04112498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relatlimab
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on Specified days
Study: NCT01115582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholic acid
Description: The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child.
Study: NCT01053585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single 'dose' 90 minutes prior to study
Study: NCT01108445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
Study: NCT01824940

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WASH
Description: WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths.
Study: NCT00810927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction cup application
Description: he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction cup application
Description: he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suction cup application
Description: he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
Study: NCT01824940

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant and young child feeding
Description: IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WASH and Nutrition
Description: WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions
Study: NCT01120444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Research Catheter with 34G x 1.5 mm needle
Description: bolus injection of insulin given intradermal prior to standardized meal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set
Description: bolus delivery of insulin given subcutaneously prior to standardized meal
Study: NCT02032212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP unflavoured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP unflavoured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP unflavoured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP unflavoured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP flavoured
Study: NCT03783663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Misfit Shine 2
Description: The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
Study: NCT03393351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making program
Description: The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
Study: NCT04165395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Five-layer foam dressing
Description: Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heelmedix boot
Description: Heelmedix boot will be installed alternately from one foot to the other.
Study: NCT02032212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP flavoured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP flavoured
Study: NCT01360333

Intervention type: OTHER
Group type: OTHER
Intervention: tap water, sodium chloride, carbohydrate rich fluid
Description: Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
Study: NCT03641001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child feeding counselling, food voucher, micronutrient powder, WASH
Description: Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
Study: NCT01712906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.50±0.25logCCID50/ml
Description: Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.50±0.25logCCID50/ml
Description: Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Study: NCT02032212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP flavoured
Study: NCT01712906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.50±0.25logCCID50/ml
Description: Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Study: NCT02032212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine inhalator
Description: 15 mg nicotine Nicorette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine inhalator
Description: 15 mg nicotine Nicorette
Study: NCT02722187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subinguinal microscopic varicocelectomy
Study: NCT02032212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine inhalator
Description: 15 mg nicotine Nicorette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine inhalator
Description: 15 mg nicotine Nicorette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarette
Study: NCT01304719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Healthy Families America Home Visitation
Description: Computer modules added to home visitation protocol for Healthy Families America

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families America Home Visitation
Description: Healthy Families America Home Visitation Treatment as Usual
Study: NCT00884598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00265642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: one tablet of 150 mg/d during 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day during 2 years
Study: NCT01426659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental stimulation according to protocol
Description: verbal stimulation every day image of the Protocol Dire et Faire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental stimulation according to protocol
Description: verbal stimulation every day image of the Protocol Dire et Faire
Study: NCT03050489

Intervention type: PROCEDURE
Intervention: On-Pump CABG.
Description: Standard On-Pump CABG.

Intervention type: PROCEDURE
Intervention: Off-Pump CABG.
Description: Standard Off-Pump CABG.

Intervention type: PROCEDURE
Intervention: BH-CABG MSC.
Description: Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
Study: NCT01031615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child and Family Traumatic Stress Interv (CFTSI)
Description: 4 sessions involving both the target child and a parent/caregiver

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Comparison
Description: 4 individually focused sessions including psychoeducation and relaxation.
Study: NCT04285684

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine in lactation
Description: 2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals